BioSpace News Archive

Grid Therapeutics , LLC today announced the initiation of a combination Phase 2 investigator-sponsored study of its lead asset, GT103.

VYNE Therapeutics Inc. today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference at the Boston Marriott Copley Place in Boston.

Cue Biopharma, Inc. (Nasdaq: CUE) announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific protein designed to induce and expand regulatory T cells (Tregs) for the treatment of autoimmune and inflammatory diseases.

Oncocyte Corporation, a precision diagnostics company, announced that it has completed the sale of 70% of its ownership stake in wholly-owned subsidiary Razor Genomics to Dragon Scientific.

Oryzon Genomics, S.A. announced that it will host a virtual panel discussion, featuring Dr. Dyanna Phillips Domilici, Dr. med. Peter Hahn, and Dr. Olga Salamero, discussing the unmet medical needs in specific central nervous system and oncology diseases.

QSAM Biosciences Inc. (OTCQB: QSAM) today announces the addition of the Ellis Fischel Cancer Center (EFCC) at the University of Missouri (MU) School of Medicine (SOM) as an upcoming clinical trial site to soon begin enrolling participants into the Phase 1 study evaluating CycloSam® for participants with multiple types of bone cancer that either originated in or has metastasized to the bone.

Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Cowen Annual Health Care Conference.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) announces that its distribution partner, Horus Pharma S.A.S. (Horus) through its Swiss affiliate Horus Pharma Suisse SA, has filed a marketing authorization application dossier for ILUVIEN® for diabetic macular edema (DME) with the Swiss Agency for Therapeutic Products (Swissmedic).

TransCode Therapeutics, Inc. today announced the signing of a non-binding letter of intent and a joint research and development agreement (JDA) with industrial biotechnology and genome editing expert, BRAIN Biotech AG.

Aquestive Therapeutics, Inc. today announced that it will report results for fourth quarter ended December 31, 2022, and provide an update on recent developments in its business after market close on Tuesday, March 7, 2023.